Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).

Inclusion Criteria:

• Alpha-feto protein > 400 ng / mL or
• prior ultrasound with mass suspicious for hepatic malignancy or.
• clinical risk of hepatocellular carcinoma or
• prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Exclusion Criteria:

• Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study
• Previous diagnosis of hepatic malignancy
• Any conditions that would discount the ability to have an MRI scan